• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Venetoclax combined with decitabine and HAAG regimen: a novel salvage strategy for relapsed/refractory T-cell acute lymphoblastic leukaemia.

作者信息

Zhu Yuanxin, Dai Yin, Tang Xiaowen

机构信息

The First Affiliated Hospital of Soochow University, Suzhou, China.

出版信息

Ann Hematol. 2022 Nov;101(11):2525-2528. doi: 10.1007/s00277-022-04912-w. Epub 2022 Sep 5.

DOI:10.1007/s00277-022-04912-w
PMID:36063200
Abstract
摘要

相似文献

1
Venetoclax combined with decitabine and HAAG regimen: a novel salvage strategy for relapsed/refractory T-cell acute lymphoblastic leukaemia.维奈托克联合地西他滨及HAAG方案：复发/难治性T细胞急性淋巴细胞白血病的一种新型挽救策略
Ann Hematol. 2022 Nov;101(11):2525-2528. doi: 10.1007/s00277-022-04912-w. Epub 2022 Sep 5.
2
Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia.维奈托克与地西他滨治疗难治性TP53突变的早期T细胞前体急性淋巴细胞白血病
Ann Hematol. 2022 Mar;101(3):697-699. doi: 10.1007/s00277-021-04530-y. Epub 2021 May 6.
3
Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case series.维奈托克联合阿扎胞苷作为复发或难治性T细胞急性淋巴细胞白血病的一种有效且安全的挽救方案：病例系列
Leuk Lymphoma. 2021 Dec;62(13):3300-3303. doi: 10.1080/10428194.2021.1957876. Epub 2021 Jul 29.
4
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.10天阿扎胞苷联合维奈克拉用于新诊断的不适合强化化疗以及复发或难治性急性髓系白血病的治疗：一项单中心2期试验
Lancet Haematol. 2020 Oct;7(10):e724-e736. doi: 10.1016/S2352-3026(20)30210-6. Epub 2020 Sep 5.
5
Venetoclax and Decitabine in Pediatric Refractory T-cell Lymphoblastic Lymphoma.维奈托克与地西他滨治疗儿童难治性T细胞淋巴母细胞淋巴瘤
J Pediatr Hematol Oncol. 2021 Oct 1;43(7):e991-e996. doi: 10.1097/MPH.0000000000002050.
6
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.在未经治疗的老年急性髓系白血病患者中，venetoclax 联合地西他滨或阿扎胞苷的安全性和初步疗效：一项非随机、开放标签、1b 期研究。
Lancet Oncol. 2018 Feb;19(2):216-228. doi: 10.1016/S1470-2045(18)30010-X. Epub 2018 Jan 12.
7
Fully oral regimen with decitabine and cedazuridine plus venetoclax: a new step forward for older or unfit patients with acute myeloid leukaemia.地西他滨和西扎珠苷加维奈克拉的全口服方案：老年或身体状况不佳的急性髓系白血病患者的新进展。
Lancet Haematol. 2024 Apr;11(4):e245-e246. doi: 10.1016/S2352-3026(24)00060-7. Epub 2024 Mar 4.
8
[Clinical efficacy and safety of venetoclax combined with multidrug chemotherapy in the treatment of 15 patients with relapsed or refractory early T-cell precursor acute lymphoblastic leukemia].维奈托克联合多药化疗治疗15例复发或难治性早期T细胞前体急性淋巴细胞白血病的临床疗效与安全性
Zhonghua Xue Ye Xue Za Zhi. 2023 Aug 14;44(8):649-653. doi: 10.3760/cma.j.issn.0253-2727.2023.08.006.
9
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab.使用地西他滨/维奈克拉和达雷妥尤单抗治疗与治疗相关的急性髓系白血病及潜在的多发性骨髓瘤。
Ann Hematol. 2021 Jun;100(6):1637-1640. doi: 10.1007/s00277-021-04490-3. Epub 2021 Mar 13.
10
Combination of Venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia: A case series from a single center.维奈托克联合低甲基化药物治疗复发/难治性急性髓系白血病：来自单中心的病例系列。
J BUON. 2021 Sep-Oct;26(5):2026-2032.

引用本文的文献

1
Underlying biology, challenges and emergent concepts in the treatment of relapsed and refractory pediatric T-cell acute lymphoblastic leukemia.复发性和难治性儿童T细胞急性淋巴细胞白血病治疗的基础生物学、挑战及新兴概念
Leukemia. 2025 Aug 14. doi: 10.1038/s41375-025-02723-2.
2
Venetoclax-based low-intensity chemotherapy in the salvage treatment of relapsed/refractory T-cell acute lymphoblastic leukemia.基于维奈托克的低强度化疗用于复发/难治性T细胞急性淋巴细胞白血病的挽救治疗
Clin Exp Med. 2025 Apr 2;25(1):104. doi: 10.1007/s10238-025-01638-7.